These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21720049)

  • 21. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity.
    Kaltsas GA; Isidori AM; Florakis D; Trainer PJ; Camacho-Hubner C; Afshar F; Sabin I; Jenkins JP; Chew SL; Monson JP; Besser GM; Grossman AB
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1645-52. PubMed ID: 11297598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly.
    Freda PU; Reyes CM; Nuruzzaman AT; Sundeen RE; Bruce JN
    Pituitary; 2003; 6(4):175-80. PubMed ID: 15237928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
    Carmichael JD; Bonert VS; Mirocha JM; Melmed S
    J Clin Endocrinol Metab; 2009 Feb; 94(2):523-7. PubMed ID: 19033371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gender- and age-related differences in the endocrine parameters of acromegaly.
    Colao A; Amato G; Pedroncelli AM; Baldelli R; Grottoli S; Gasco V; Petretta M; Carella C; Pagani G; Tambura G; Lombardi G
    J Endocrinol Invest; 2002 Jun; 25(6):532-8. PubMed ID: 12109625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up of patients with elevated IGF-1 and nadir GH > 0.4 µg/L but < 1 µg/L.
    Rosario PW; Calsolari MR
    Arch Endocrinol Metab; 2017; 61(5):426-431. PubMed ID: 28977166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical, hormonal and magnetic resonance imaging (MRI) predictors of transsphenoidal surgery outcome in acromegaly.
    Bourdelot A; Coste J; Hazebroucq V; Gaillard S; Cazabat L; Bertagna X; Bertherat J
    Eur J Endocrinol; 2004 Jun; 150(6):763-71. PubMed ID: 15191345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Value of Early Post-Operative Growth Hormone Testing in Predicting Long-Term Remission and Residual Disease after Transsphenoidal Surgery for Acromegaly.
    Wang YY; Waqar M; Abou-Zeid A; Kearney T; Caputo C; Davis J; Trainer P; Higham C; Roncaroli F; Gnanalingham KK
    Neuroendocrinology; 2022; 112(4):345-357. PubMed ID: 34052822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth hormone after oral glucose overload: revision of reference values in normal subjects.
    Rosário PW; Furtado MS
    Arq Bras Endocrinol Metabol; 2008 Oct; 52(7):1139-44. PubMed ID: 19082302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Outcome of surgical treatment for acromegaly performed by a single neurosurgeon and cumulative meta-analysis].
    Boeving A; Borba LA; Rodrigues AM; Orichowski EB; Paz Filho GJ; Santos CM; Boguszewski CL
    Arq Bras Endocrinol Metabol; 2006 Oct; 50(5):884-92. PubMed ID: 17160212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of nadir GH levels for long-term biochemical remission or recurrence in surgically treated acromegaly.
    Freda PU; Bruce JN; Reyes-Vidal C; Singh S; DeLeon Y; Jin Z; Khandji AG; Cremers S; Post KD
    Pituitary; 2021 Apr; 24(2):170-183. PubMed ID: 33124000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current concepts in the biochemical assessment of the patient with acromegaly.
    Freda PU
    Growth Horm IGF Res; 2003 Aug; 13(4):171-84. PubMed ID: 12914750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low insulin resistance after surgery predicts poor GH suppression one year after complete resection for acromegaly: a retrospective study.
    Edo N; Morita K; Suzuki H; Takeshita A; Miyakawa M; Fukuhara N; Nishioka H; Yamada S; Takeuchi Y
    Endocr J; 2016 May; 63(5):469-77. PubMed ID: 26949262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly.
    Biermasz NR; van Dulken H; Roelfsema F
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4596-602. PubMed ID: 11134114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Growth hormone responses to oral glucose and intravenous thyrotropin-releasing hormone in acromegalic patients treated by slow-release lanreotide.
    Díez JJ; Iglesias P; Gómez-Pan A
    J Endocrinol Invest; 2001 May; 24(5):303-9. PubMed ID: 11407648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postoperative persistent thyrotrophin releasing hormone-induced growth hormone release predicts recurrence in patients with acromegaly.
    Biermasz NR; Smit JW; van Dulken H; Roelfsema F
    Clin Endocrinol (Oxf); 2002 Mar; 56(3):313-9. PubMed ID: 11940042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
    Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
    J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value of early postoperative random growth hormone levels and nadir growth hormone levels after oral glucose tolerance testing in acromegaly.
    Rotermund R; Burkhardt T; Rohani Z; Jung R; Aberle J; Flitsch J
    Growth Horm IGF Res; 2018 Aug; 41():64-70. PubMed ID: 29555234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels.
    Feelders RA; Bidlingmaier M; Strasburger CJ; Janssen JA; Uitterlinden P; Hofland LJ; Lamberts SW; van der Lely AJ; de Herder WW
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6480-9. PubMed ID: 16159936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values?
    Brzana JA; Yedinak CG; Delashaw JB; Gultelkin HS; Cook D; Fleseriu M
    Pituitary; 2012 Dec; 15(4):562-70. PubMed ID: 22183781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of surgical outcome and early criteria of remission in acromegaly.
    Antunes X; Ventura N; Camilo GB; Wildemberg LE; Guasti A; Pereira PJM; Camacho AHS; Chimelli L; Niemeyer P; Gadelha MR; Kasuki L
    Endocrine; 2018 Jun; 60(3):415-422. PubMed ID: 29626274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.